Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1126/science.abc1932

http://scihub22266oqcxt.onion/10.1126/science.abc1932
suck pdf from google scholar
32376603!7202686!32376603
unlimited free pdf from europmc32376603    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32376603      Science 2020 ; 369 (6499): 77-81
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Development of an inactivated vaccine candidate for SARS-CoV-2 #MMPMID32376603
  • Gao Q; Bao L; Mao H; Wang L; Xu K; Yang M; Li Y; Zhu L; Wang N; Lv Z; Gao H; Ge X; Kan B; Hu Y; Liu J; Cai F; Jiang D; Yin Y; Qin C; Li J; Gong X; Lou X; Shi W; Wu D; Zhang H; Zhu L; Deng W; Li Y; Lu J; Li C; Wang X; Yin W; Zhang Y; Qin C
  • Science 2020[Jul]; 369 (6499): 77-81 PMID32376603show ga
  • The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
  • |*Viral Vaccines/administration & dosage/adverse effects/immunology[MESH]
  • |Animals[MESH]
  • |Antibodies, Neutralizing/biosynthesis/*blood/immunology[MESH]
  • |Antibodies, Viral/biosynthesis/*blood/immunology[MESH]
  • |Betacoronavirus/*immunology/isolation & purification[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Vaccines[MESH]
  • |Chlorocebus aethiops[MESH]
  • |Coronavirus Infections/immunology/*prevention & control/virology[MESH]
  • |Dose-Response Relationship, Immunologic[MESH]
  • |Female[MESH]
  • |Immunogenicity, Vaccine[MESH]
  • |Immunoglobulin G/biosynthesis/blood/immunology[MESH]
  • |Macaca mulatta[MESH]
  • |Male[MESH]
  • |Mice[MESH]
  • |Mice, Inbred BALB C[MESH]
  • |Pandemics/*prevention & control[MESH]
  • |Pilot Projects[MESH]
  • |Pneumonia, Viral/*prevention & control/virology[MESH]
  • |Rats[MESH]
  • |Rats, Wistar[MESH]
  • |SARS-CoV-2[MESH]
  • |Vaccines, Inactivated/administration & dosage/adverse effects/immunology[MESH]
  • |Vero Cells[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box